---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-045465"
form_type: "8-K"
ticker: "WHWK"
cik: "0001422142"
company_name: "Whitehawk Therapeutics, Inc."
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:27:07.037850+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aadi Bioscience Q3 2024 FYARRO sales $7.2M (+21% YoY); net loss $12.5M

## Summary
- FYARRO net product sales of $7.2M in Q3 2024, up 17% from Q2 2024 and 21% from prior year.
- Net loss of $12.5M for Q3 2024 vs $16.3M for Q3 2023; operating expenses $20.6M incl $2.6M restructuring.
- Cash, equivalents, and short-term investments $62.6M as of Sep 30, 2024; expected to fund ops into 2H 2026.
- Completed wind-down of PRECISION1 trial; Phase 2 trials for EEC and NETs enrolled 24 and 12 patients.
- Comprehensive strategic review ongoing to maximize shareholder value; no timeline provided.

## SEC filing metadata
- accession: 0001628280-24-045465
- form_type: 8-K
- ticker: WHWK
- cik: 0001422142
- company_name: Whitehawk Therapeutics, Inc.
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422142/000162828024045465/0001628280-24-045465-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422142/000162828024045465/aadi-20241106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-045465
- JSON: https://secwatch.observer/filing/0001628280-24-045465.json
- Plain text: https://secwatch.observer/filing/0001628280-24-045465.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.